09:20 AM EDT, 03/12/2024 (MT Newswires) -- Pfizer ( PFE ) said Tuesday that a phase 3 study of Adcetris in combination with lenalidomide and rituximab to treat patients with relapsed/refractory diffuse large B-cell lymphoma demonstrated a "statistically significant and clinically meaningful improvement" in the primary endpoint of overall survival.

There were also positive outcomes in secondary endpoints that included progression free survival and overall response rate, the company added.

The Echelon-3 trial, which evaluated 230 participants, showed that the safety and tolerability of Adcetris were "consistent" with what had been previously presented, Pfizer ( PFE ) said.

The drug maker said it plans to share the trial data with the Food and Drug Administration to potentially support regulatory filing in the US.

Price: 28.33, Change: -0.04, Percent Change: -0.14